Evidence map›Paper›PMID 37423944›Full record

ArticleActa diabetologica2023

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy.

Kuebra Oezer, Matthias Kolibabka, Johann Gassenhuber, Nadine Dietrich, Thomas Fleming, Andrea Schlotterer, Michael Morcos, Paulus Wohlfart, Hans-Peter Hammes

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta diabetologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this map
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kuebra Oezer5th Medical Department, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Kuebra.Acunman@gmail.com.ORCID http://orcid.org/0000-0002-7715-9816
Matthias Kolibabka5th Medical Department, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Johann GassenhuberSanofi, MSAT M&I Bioassays and Compliance, Frankfurt, Germany.
Nadine Dietrich5th Medical Department, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Thomas FlemingDepartment of Medicine I and Clinical Chemistry, Heidelberg University, Heidelberg, Germany.
Andrea Schlotterer5th Medical Department, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Michael Morcos5th Medical Department, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Paulus WohlfartSanofi, MSAT M&I Bioassays and Compliance, Frankfurt, Germany.
Hans-Peter Hammes5th Medical Department, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Heidelberg University · DESanofi (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsGlucagon-like peptide-1 receptor agonists are effective treatments for type 2 diabetes, effectively lowering glucose without weight gain and with low risk for hypoglycemia. However, their influence on the retinal neurovascular unit remains unclear. In this study, we analyzed the effects of the GLP-1 RA lixisenatide on diabetic retinopathy.

methodsVasculo- and neuroprotective effects were assessed in experimental diabetic retinopathy and high glucose-cultivated C. elegans, respectively. In STZ-diabetic Wistar rats, acellular capillaries and pericytes (quantitative retinal morphometry), neuroretinal function (mfERG), macroglia (GFAP western blot) and microglia (immunohistochemistry) quantification, methylglyoxal (LC-MS/MS) and retinal gene expressions (RNA-sequencing) were determined. The antioxidant properties of lixisenatide were tested in C. elegans.

resultsLixisenatide had no effect on glucose metabolism. Lixisenatide preserved the retinal vasculature and neuroretinal function. The macro- and microglial activation was mitigated. Lixisenatide normalized some gene expression changes in diabetic animals to control levels. Ets2 was identified as a regulator of inflammatory genes. In C. elegans, lixisenatide showed the antioxidative property.

conclusionsOur data suggest that lixisenatide has a protective effect on the diabetic retina, most likely due to a combination of neuroprotective, anti-inflammatory and antioxidative effects of lixisenatide on the neurovascular unit.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diabetic RetinopathyAnimalsAntioxidantsCaenorhabditis elegansChromatography, LiquidGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 ReceptorGlucoseHypoglycemic AgentsPeptidesRatsRats, WistarTandem Mass SpectrometryAntioxidantsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 ReceptorGlucoseHypoglycemic AgentslixisenatidePeptidesDiabetic retinopathyEts2GLP-1RALixisenatideNeurovascular unitROS

Identifiers

PMID37423944
PMCPMC10520173
OpenAlexW4383676238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.